INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 281 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2022. The put-call ratio across all filers is 0.83 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $22,993,063 | -13.5% | 441,410 | +5.1% | 0.02% | -10.0% |
| Q2 2023 | $26,582,137 | +43.2% | 419,806 | +22.3% | 0.02% | +33.3% |
| Q1 2023 | $18,559,513 | +3.3% | 343,377 | +1.1% | 0.02% | 0.0% |
| Q4 2022 | $17,974,912 | +21.6% | 339,662 | +6.9% | 0.02% | +15.4% |
| Q3 2022 | $14,787,000 | -18.9% | 317,795 | -0.5% | 0.01% | -13.3% |
| Q2 2022 | $18,226,000 | +56.2% | 319,299 | +67.5% | 0.02% | +87.5% |
| Q1 2022 | $11,666,000 | +2242.6% | 190,663 | +1905.5% | 0.01% | – |
| Q4 2021 | $498,000 | +55.1% | 9,507 | +10.3% | 0.00% | – |
| Q3 2021 | $321,000 | -0.6% | 8,621 | +8.9% | 0.00% | – |
| Q2 2021 | $323,000 | -65.9% | 7,918 | -87.9% | 0.00% | -100.0% |
| Q4 2017 | $946,000 | -8.2% | 65,330 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $1,031,000 | -45.7% | 65,330 | +33.6% | 0.00% | -50.0% |
| Q2 2016 | $1,898,000 | – | 48,896 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 640,000 | $25,626,000 | 6.33% |
| Redmile Group, LLC | 1,322,592 | $52,957,000 | 4.01% |
| SENZAR ASSET MANAGEMENT, LLC | 556,224 | $22,271,209,000 | 3.24% |
| RA Capital Management | 314,349 | $12,587,000 | 1.81% |
| WALL STREET ASSOCIATES | 205,657 | $8,235,000 | 1.58% |
| Parametrica Management Ltd | 5,400 | $216,000 | 1.36% |
| Rhenman & Partners Asset Management AB | 165,000 | $6,607,000 | 1.05% |
| EAM Investors, LLC | 95,168 | $3,811,000 | 0.60% |
| Rock Springs Capital Management LP | 180,000 | $7,207,000 | 0.58% |
| WASATCH ADVISORS LP | 1,085,973 | $43,482,000 | 0.58% |